McDevitt D G, Nelson J K
Br J Clin Pharmacol. 1978 Sep;6(3):233-7. doi: 10.1111/j.1365-2125.1978.tb04590.x.
1 The use of atenolol, a cardioselective beta-adrenoceptor antagonist, in the management of hyperthyroidism has been studied by comparing it with propranolol. 2 In a double-blind cross-over trial, atenolol (50 mg), propranolol (40 mg) and placebo 4 times daily for 1 week were compared in twenty-one hyperthyroid patients by sequential analysis. 3. Patients generally preferred atenolol or propranolol to placebo but this preference only achieved significance with propranolol. 4 Judged by their effect on the symptoms and signs of hyperthyroidism, both atenolol and propranolol were significantly better than placebo, but no distinction could be made between the two active compounds. 5 Atenolol and propranolol reduced mean heart rate by 29.8 and 27.1% respectively compared with placebo. 6 Atenolol appeared almost equally effective to propranolol in the management of the peripheral manifestations of hyperthyroidism.
已通过将阿替洛尔（一种心脏选择性β - 肾上腺素能受体拮抗剂）与普萘洛尔进行比较，研究了其在甲状腺功能亢进治疗中的应用。
在一项双盲交叉试验中，通过序贯分析比较了21例甲状腺功能亢进患者每日4次服用阿替洛尔（50毫克）、普萘洛尔（40毫克）和安慰剂，持续1周的情况。
患者通常更喜欢阿替洛尔或普萘洛尔而非安慰剂，但这种偏好仅在普萘洛尔组具有统计学意义。
从它们对甲状腺功能亢进症状和体征的影响来看，阿替洛尔和普萘洛尔均显著优于安慰剂，但两种活性化合物之间无显著差异。
与安慰剂相比，阿替洛尔和普萘洛尔分别使平均心率降低了29.8%和27.1%。
在甲状腺功能亢进的外周表现管理方面，阿替洛尔似乎与普萘洛尔效果几乎相同。
